



---

Year: 2019

---

## Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma

von der Grün, Jens ; Winkelmann, Ria ; Meissner, Markus ; Wieland, Ulrike ; Silling, Steffi ; Martin, Daniel ; Fokas, Emmanouil ; Rödel, Claus ; Rödel, Franz ; Balermipas, Panagiotis

**Abstract:** Introduction: Merkel cell carcinoma (MCC) is linked to the presence of clonally integrated Merkel cell polyomavirus (MCPyV) in up to 80% of the cases. The aim of the study was to determine the prognostic value of baseline MCPyV viral load and lymphocytic infiltration. Methods: MCPyV DNA prevalence, integration status and viral load were determined by specific quantitative real-time PCR in surgical specimens obtained from 49 patients with MCC treated with (n = 22, 45%) or without postoperative radiotherapy (RT). CD8+ tumor infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) status were assessed using immunohistochemistry. MCPyV characteristics and immune marker expression were correlated with clinicopathological factors and overall survival (OS). Results: Median age at diagnosis was 74 (range, 42–100); 51% of the patients were female. One-, three, and five-year OS rates were 83.8, 58.6, and 47.1%, respectively. A positive MCPyV status was associated with female gender (p = 0.042). Tumor localization (head/arms vs. trunk) positively correlated with PD-L1 status (p = 0.011) and combined CD8/PD-L1 expression (p = 0.038). Overall CD8+ infiltration was inversely associated with N-stage (p = 0.048). Stromal TILs correlated significantly with both PD-L1 expression (p = 0.010) and N-stage (p = 0.037). A high viral load (>median) was significantly associated with worse OS (p = 0.029) and high intratumoral CD8+ infiltration with improved OS for the entire cohort (p = 0.045). Conclusion: These data provide important insight on the role of MCPyV DNA viral load and TILs in the context of PD-L1 in patients with Merkel cell carcinoma. Future clinical studies should aim to explore the effect of PD-1/PD-L1 immune-checkpoint inhibitors in combination with existing radiotherapy approaches.

DOI: <https://doi.org/10.3389/fonc.2019.00020>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-184285>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:

von der Grün, Jens; Winkelmann, Ria; Meissner, Markus; Wieland, Ulrike; Silling, Steffi; Martin, Daniel; Fokas, Emmanouil; Rödel, Claus; Rödel, Franz; Balermipas, Panagiotis (2019). Merkel Cell Polyoma

Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma. *Frontiers in Oncology*, 9:20.  
DOI: <https://doi.org/10.3389/fonc.2019.00020>



# Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma

Jens von der Grün<sup>1†</sup>, Ria Winkelmann<sup>2†</sup>, Markus Meissner<sup>3</sup>, Ulrike Wieland<sup>4</sup>, Steffi Silling<sup>4</sup>, Daniel Martin<sup>1</sup>, Emmanouil Fokas<sup>1,5,6</sup>, Claus Rödel<sup>1,5,6</sup>, Franz Rödel<sup>1,5,6</sup> and Panagiotis Balermas<sup>1,5,6,7\*</sup>

<sup>1</sup> Department of Radiotherapy and Oncology, University of Frankfurt, Frankfurt, Germany, <sup>2</sup> Dr. Senckenberg Institute of Pathology, University of Frankfurt, Frankfurt, Germany, <sup>3</sup> Department of Dermatology, University of Frankfurt, Frankfurt, Germany, <sup>4</sup> Institute of Virology, National Reference Center for Papilloma and Polyomaviruses, University of Cologne, Cologne, Germany, <sup>5</sup> German Cancer Research Center (DKFZ), Heidelberg, Germany, <sup>6</sup> German Cancer Consortium (DKTK) Partner Site Frankfurt, Frankfurt, Germany, <sup>7</sup> Department of Radiation Oncology, University Hospital Zürich, Zurich, Switzerland

## OPEN ACCESS

### Edited by:

Peter Brossart,  
Universität Bonn, Germany

### Reviewed by:

Daniel Olive,  
Aix Marseille Université, France  
Graham Robert Leggatt,  
The University of Queensland,  
Australia

### \*Correspondence:

Panagiotis Balermas  
panagiotis.balermas@usz.ch

<sup>†</sup>These authors have contributed  
equally to this work

### Specialty section:

This article was submitted to  
Cancer Immunity and Immunotherapy,  
a section of the journal  
Frontiers in Oncology

Received: 19 October 2018

Accepted: 07 January 2019

Published: 24 January 2019

### Citation:

von der Grün J, Winkelmann R,  
Meissner M, Wieland U, Silling S,  
Martin D, Fokas E, Rödel C, Rödel F  
and Balermas P (2019) Merkel Cell  
Polyoma Viral Load and Intratumoral  
CD8+ Lymphocyte Infiltration Predict  
Overall Survival in Patients With Merkel  
Cell Carcinoma. *Front. Oncol.* 9:20.  
doi: 10.3389/fonc.2019.00020

**Introduction:** Merkel cell carcinoma (MCC) is linked to the presence of clonally integrated Merkel cell polyomavirus (MCPyV) in up to 80% of the cases. The aim of the study was to determine the prognostic value of baseline MCPyV viral load and lymphocytic infiltration.

**Methods:** MCPyV DNA prevalence, integration status and viral load were determined by specific quantitative real-time PCR in surgical specimens obtained from 49 patients with MCC treated with ( $n = 22$ , 45%) or without postoperative radiotherapy (RT). CD8+ tumor infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) status were assessed using immunohistochemistry. MCPyV characteristics and immune marker expression were correlated with clinicopathological factors and overall survival (OS).

**Results:** Median age at diagnosis was 74 (range, 42–100); 51% of the patients were female. One-, three, and five-year OS rates were 83.8, 58.6, and 47.1%, respectively. A positive MCPyV status was associated with female gender ( $p = 0.042$ ). Tumor localization (head/arms vs. trunk) positively correlated with PD-L1 status ( $p = 0.011$ ) and combined CD8/PD-L1 expression ( $p = 0.038$ ). Overall CD8+ infiltration was inversely associated with N-stage ( $p = 0.048$ ). Stromal TILs correlated significantly with both PD-L1 expression ( $p = 0.010$ ) and N-stage ( $p = 0.037$ ). A high viral load (>median) was significantly associated with worse OS ( $p = 0.029$ ) and high intratumoral CD8+ infiltration with improved OS for the entire cohort ( $p = 0.045$ ).

**Conclusion:** These data provide important insight on the role of MCPyV DNA viral load and TILs in the context of PD-L1 in patients with Merkel cell carcinoma. Future clinical studies should aim to explore the effect of PD-1/PD-L1 immune-checkpoint inhibitors in combination with existing radiotherapy approaches.

**Keywords:** merkel cell carcinoma, polyomavirus (MCPyV), CD8+ tumor infiltrating lymphocytes, PD-L1, radioimmunotherapy

## INTRODUCTION

Merkel cell carcinoma (MCC) is a rare neuroendocrine, cutaneous malignancy with an incidence rate of 0.13 per 1,00,000 residents in Europe between 1995 and 2002 (1). Therapy consists of surgery only (if N0), surgery followed in most cases by adjuvant radiotherapy (RT) or, more recently, by novel approaches, including immune-checkpoint inhibitors (ICI) in metastatic disease (2–4). The 5-year MCC-specific mortality rate is up to 46% (5, 6). MCC tumorigenesis is linked to the presence of clonally integrated Merkel cell polyomavirus (MCPyV) in up to 80% of the cases, or mutagenesis from ultraviolet light (UV) exposure for MCPyV-negative tumors, as well as advanced age and immunosuppression (3, 7). MCPyV integrates into the host cells genome and persistent expression of MCPyV T antigens is required for MCC tumor cell survival (8). Immunosuppression due to, e.g., organ transplantation or chronic lymphatic leukemia significantly increases the risk for MCC, thus indicating a pivotal role of the host immune system in tumorigenesis (7).

Although it has been reported that patients with high intratumoral CD8+ and CD4+ lymphocyte infiltration show better clinical outcome, including complete spontaneous tumor regression (9–11), the majority of MCC tumors progress despite the presence of T-cells priming MCPyV capsid proteins and oncoproteins. MCC seems to be capable of escaping immune response via down-regulation of major histocompatibility complex class I (MHC-I), Toll-like Receptor 9 (TLR9), and prevention of NF- $\kappa$ B translocation into the nucleus (8, 12). Upregulation of programmed death ligand 1 (PD-L1) expression in response to interferon- $\gamma$ , released by CD8+ TILs as an adaptive immune-resistance mechanism, can suppress local effector T-cell function. ICI against the PD-1/PD-L1 axis have shown promising results in the treatment of metastatic MCC, and recently resulted in the approval of Avelumab (anti-PD-L1) by the Food and Drug Administration (FDA) (4).

In this study we aimed to correlate MCPyV quantitative viral load, CD8+ tumor infiltrating lymphocytes (TILs), and PD-L1 expression with clinicopathological characteristics and overall survival (OS) in patients with MCC.

## PATIENTS AND METHODS

### Patients and Treatment

We retrospectively analyzed 49 patients treated for histologically-proven MCC between June 2000 and September 2017 at the Departments of Dermatology and/or Radiotherapy of the University of Frankfurt, Germany. All patients underwent physical examination and complete tumor excision. In case of >cT1 or cN1 cM0, a sentinel lymph node biopsy (SLNB) was performed, followed, in case of positive SLNB, by a regional lymph node dissection and in most cases by adjuvant RT. Depending on tumor site and volume, RT was administered using 3D-conformal or intensity-modulated radiotherapy (IMRT, since 2010) utilizing photon or electron beams and energies  $\geq 6$  MV. RT-doses ranged between 20.0 and 70.0 Gray (Gy, median: 60.0 Gy). All patients provided informed consent for sample and clinical data collection. All procedures performed in this study

followed approval of our institutional ethics committee (No. 4/09 UCT-03-2017) and were in accordance with the standards of the 1964 Helsinki declaration and its later amendments.

### Immunohistochemistry

Formalin fixed paraffin embedded (FFPE) tumor samples derived from the Dr. Senckenberg Institute of Pathology, and the Department of Dermatology, University of Frankfurt, were subjected to an automatic staining procedure with standardized DAKO EnVision™ FLEX Peroxidase Blocking reagent (K8000, DAKO, Hamburg, Germany) on a DAKO Autostainer Link 48 (DAKO). Antigen retrieval was performed by treatment of the sections using an Epitope Retrieval Solution (Trilog, Cell Marque, Rocklin, CA) for 20 min. Slides were stained with the primary antibodies for either CD8 (1:100, clone C8/144B; Dako M7103) or PD-L1 (1:50, clone E1L3N(R); Cell Signaling Technology) for 120 min at room temperature. Next, dextran polymer conjugated horseradish peroxidase and 3,3'-diamino-benzidine (DAB) chromogen were used for visualization and hematoxylin solution (Gill 3, Sigma Aldrich, Munich, Germany) for counterstaining. Blinded samples were evaluated by two investigators (J.V. and P.B.) without knowledge of the clinicopathologic and clinical data as described before (13, 14). In cases of discrepancy, a final decision was made after additional examination of the specimens. The expression of CD8+ TILs was scored semi-quantitatively via measurement of cell density. Scoring was as follows: for the intra-epithelial, invasive front and stromal compartments: (i) no, or sporadic cells; (ii) moderate numbers of cells; (iii) abundant occurrence of cells; and (iv) highly abundant occurrence of cells. The total score was calculated by adding the separate scores from all three compartments (range, 3–12). The median score was used as cut-off to classify patients into two groups: low (<median) or high ( $\geq$ median) CD8+ infiltration. PD-L1 tumor expression as evaluated for each sample in different representative fields and expression in >1% of the tumor cells were considered positive as reported before (15).

### MCPyV Detection and DNA Load Determination

Determination of MCPyV DNA load and MCPyV integration status were performed on five 10  $\mu$ m FFPE sections using a LightCycler 480 Real Time PCR System (Roche, Mannheim, Germany) as described previously (16, 17). Briefly, viral DNA load was determined using MCPyV-specific LT3-primers and a locked nucleic acid probe binding to the N-terminal part of the large T-antigen gene (18). MCPyV DNA load was expressed as MCPyV DNA copies per betaglobin-gene copy (17). The integration status of the MCPyV DNA into the cellular host genome was assessed with a real-time PCR-based MCPyV T-antigen gene C-terminus deletion assay as described before (16). For statistical analysis, a non-detectable viral DNA load was defined as 0 and the median was calculated for the entire cohort ( $n = 48$ ).

### Statistical Analysis

The association of MCPyV, CD8+ infiltration and PD-L1 expression with clinicopathological characteristics was assessed

using Pearson's Chi-squared test for categorical variables and Mann-Whitney U test for continuous variables. The clinical outcome measure was overall survival (OS) as defined from the time-point of histologically confirmed diagnosis of MCC to death from any cause. Differences in OS between groups were plotted using the Kaplan–Meier method and assessed using the Log-rank test (Mantel-Cox; SPSS 25). A  $p < 0.05$  was considered as significant.

## RESULTS

### Patients and Tumor Characteristics

From a total of 49 patients, 25 (51.0%) were female. Median age at diagnosis was 74 (range, 42–100) years. The head was the main tumor site (45.5%), followed by arms (34.0%), and body trunk (20.5%). A total of 54.5% of the patients had positive lymph nodes, and 44.9% received adjuvant RT. Concerning the MCPyV-DNA status, 1 MCC was not evaluable due to low cellularity (betaglobin-gene copy number  $< 10$ ), 38 of the remaining 48 biopsies were MCPyV-DNA positive (79.2%), and 10 MCC (20.8%) were MCPyV-negative. The median viral DNA load for the entire cohort ( $n = 48$ ) was 0.745 (interquartile range 0.007–4.448; mean 7.072; range 0.000–157.007). Integrated, C-terminally deleted MCPyV-DNA was found in 22.9% of all patients (11/48), episomal or full-length integrated MCPyV-DNA in 33.3% of all patients (16/48), and in 22.9% of the entire cohort (11/48) the integration status could not be evaluated or was negative (20.8%, 10/48). Patient characteristics are given in Table 1.

### Clinicopathological Characteristics and Their Association With MCPyV Status, CD8 Infiltration, and PD-L1 Expression

For CD8+ TILs, the median score was used as cut-off to dichotomize between low and high infiltration, whereas PD-L1+ expression in  $>1\%$  of the tumor cells was considered positive (Figure 1). Tumor localization (head/arms vs. trunk) positively correlated with PD-L1 status ( $p = 0.011$ , Table 2) and combined CD8/PD-L1 expression ( $p = 0.038$ , Supplementary Table 2). Overall CD8+ infiltration was inversely associated with N-stage ( $p = 0.048$ , Table 2). A high stromal CD8+ infiltration was associated with PD-L1 positivity ( $p = 0.010$ ) and N-stage ( $p = 0.037$ , Table 3). Further, a positive MCPyV status and high viral DNA load were associated with female gender ( $p = 0.042$  and  $0.021$ , respectively) (Table 2 and Supplementary Table 1).

### Overall Survival and Correlation With MCPyV DNA Load, CD8, and PD-L1

One-, three-, and five-year OS rates were 83.8, 58.6, and 47.1%, respectively (Figure 2). Cumulative ( $p = 0.078$ ) and stromal ( $p = 0.279$ ) expression of CD8+ TILs were not associated with OS, whereas elevated levels of intratumoral CD8+ cells correlated significantly with superior OS for the entire cohort ( $p = 0.045$ , Figure 2). High levels of DNA viral load ( $>$ median) were significantly

**TABLE 1 |** Patients characteristics.

| Clinical characteristics           | n (%)       |
|------------------------------------|-------------|
| <b>Total (n = 49)</b>              |             |
| <b>GENDER</b>                      |             |
| Male                               | 24 (49.0)   |
| Female                             | 25 (51.0)   |
| Age, median (range)                | 74 (42–100) |
| <b>TUMOR LOCALIZATION</b>          |             |
| Head                               | 20 (45.5)   |
| Arm                                | 15 (34.0)   |
| Body trunk                         | 9 (20.5)    |
| Missing values                     | 5           |
| <b>cN-CATEGORY</b>                 |             |
| cN0                                | 15 (45.5)   |
| cN+                                | 18 (54.5)   |
| Missing values                     | 16          |
| <b>CD8 SCORE<sup>‡</sup></b>       |             |
| $<$ median                         | 25 (51.0)   |
| $\geq$ median                      | 24 (49.0)   |
| <b>PD-L1*</b>                      |             |
| $\leq 1\%$                         | 21 (42.9)   |
| $> 1\%$                            | 28 (57.1)   |
| <b>MCPyV DNA STATUS</b>            |             |
| Positive                           | 38 (79.2)   |
| Negative                           | 10 (20.8)   |
| Not assessable                     | 1           |
| <b>VIRAL INTEGRATION STATUS</b>    |             |
| Integrated, C-terminally deleted   | 11 (22.9%)  |
| Episomal or full-length integrated | 16 (33.3%)  |
| Integration status not assessable  | 11 (22.9%)  |
| MCPyV-negative                     | 10 (20.8%)  |
| Missing values                     | 1           |
| <b>RADIOTHERAPY</b>                |             |
| Yes                                | 22 (44.9)   |
| No                                 | 27 (55.1)   |


MCPyV, Merkel Cell Polyomavirus. \*% PD-L1+ tumor cells. <sup>‡</sup>CD8+ tumor infiltration.

related to a worse OS ( $p = 0.029$ , Figure 3). The association remained significant after exclusion of cases that lack detectable viral DNA ( $p = 0.034$  for  $n = 38$ , Supplementary Figure 1). PD-L1-positivity did not correlate with OS ( $p = 0.966$ ).

## DISCUSSION

MCC is an aggressive disease with various options of the malignant cells to avoid immune response. Accumulating evidence indicates a direct association of higher “immunogenicity” and response to RT in MCC (19), and other virus-associated malignancies, including HPV-16/18 induced oropharyngeal and anal carcinoma (13, 20, 21). A recent investigation in 805 patients with MCC indicated a significantly impaired efficacy of RT in terms of local tumor control and





**FIGURE 1** | Immunohistochemical staining of CD8 and PD-L1. **(A)** CD8: low: <median score of 5, **(B)** high:  $\geq$ median score of 5 (range 3–12); **(C)** PD-L1:  $\leq 1\%$  positive tumor cells (low) and **(D)**  $> 1\%$  positive tumor cells (high).

recurrence-free survival for patients with immunosuppression (22). Further understanding of tumor driving mechanisms may lead to new strategies facing this rare tumor entity.

In the present study, we quantitatively evaluated the prevalence, viral load, and genomic integration into the host DNA of MCPyV in a cohort of MCC-patients and correlated these parameters with OS, PD-L1 status, and CD8+ lymphocyte infiltration. To the best of our knowledge, this is the first study investigating the relationship between MCPyV viral load and survival (9, 23). Vandeven et al. could demonstrate that MCC of unknown primary (MCUP) was associated with higher levels of MCPyV-antibodies and higher mutational load, as surrogate parameters for immunogenicity, and correlated with improved survival when compared to patients with identified primary tumors (24). Additionally, other authors have reported a positive correlation of a high antibody titer with MCPyV status and OS for classical MCC (18, 25, 26). These data provide a strong rationale for a virus-triggered effective immune-activation as a pivotal mechanism underlying tumor elimination.

Intriguingly, a high viral load correlated with worse OS in our cohort while tumors with a lower load or lack of viral DNA displayed increased OS. MCPyV negative tumors are mainly considered to be induced by ultraviolet radiation and present a high mutational burden in general and more specifically high incidence of p53 (75%) and Rb mutations (67%) (27, 28). Emerging evidence shows a clear association of mutational load and prognosis for almost any malignancy, a phenomenon

associated with the increased immunogenicity of such tumors (29). The percentage of non-virally induced tumors in our cohort is in accordance with the literature (28, 30). These extensively—mutated cases could have an even better outcome compared to MCPyV-driven tumors, such as biasing the survival-analysis. Moreover, a less favorable outcome for MCPyV negative tumors has been reported before (25, 31). However, the significance for the correlation of high viral load and OS still remained after exclusion of cases without any detectable viral DNA. A possible reason for the impaired survival of patients with high viral-load is a missing or ineffective immune response due to immunosuppression or various cancer- and microenvironment-associated mechanisms, including alteration of regulatory T cell function and activation of the PD-1/PD-L1 axis (32, 33). Notably, similar findings have been reported for Epstein-Barr-Virus (EBV) associated nasopharyngeal cancer, where a high EBV-DNA load in the plasma correlated with an impaired outcome (34, 35).

Until the advent of ICI, chemotherapy was standard of care in the treatment of advanced MCC. First-line platinum-based chemotherapy combined with Etoposide showed overall response rates (ORR) of 31–55% with shorter progression-free survival than those recently reported for anti-PD-1/PD-L1 ICI (3). In a recent phase 2 trial the anti-PD-L1 antibody Avelumab was applied to 88 patients with stage IV MCC that had progressed after chemotherapy. Objective response was reached in 32% of the patients indicating superiority of novel immune-modulating therapies (2). These findings resulted in the first approval of a checkpoint inhibitor in MCC (4).

**TABLE 2 |** Clinicopathological characteristics and their association with MCPyV status and immune microenvironment.

| Clinico-pathological characteristics | MCPyV status, <i>n</i> (%) |              | <i>p</i> <sup>†</sup> | CD8 <sup>‡</sup> , <i>n</i> (%) |              | <i>p</i> <sup>†</sup> | PD-L1*, <i>n</i> (%) |              | <i>p</i> <sup>†</sup> |
|--------------------------------------|----------------------------|--------------|-----------------------|---------------------------------|--------------|-----------------------|----------------------|--------------|-----------------------|
|                                      | Negative <sup>#</sup>      | Positive     |                       | <Median                         | ≥Median      |                       | ≤1%                  | >1%          |                       |
| N-STAGE ( <i>n</i> = 33)             |                            |              |                       |                                 |              |                       |                      |              |                       |
| Negative                             | 7<br>(46.7)                | 8<br>(53.3)  | 0.653                 | 4<br>(26.7)                     | 11<br>(73.3) | 0.048                 | 7<br>(46.7)          | 8<br>(53.3)  | 0.653                 |
| Positive                             | 7<br>(38.9)                | 11<br>(61.1) |                       | 11<br>(61.1)                    | 7<br>(38.9)  |                       | 7<br>(38.9)          | 11<br>(61.1) |                       |
| TUMOR LOCALIZATION ( <i>n</i> = 45)  |                            |              |                       |                                 |              |                       |                      |              |                       |
| Head or arms                         | 16<br>(45.7)               | 19<br>(54.3) | 0.504                 | 20<br>(57.1)                    | 15<br>(42.9) | 0.062                 | 16<br>(45.7)         | 19<br>(54.3) | 0.011                 |
| Other                                | 3<br>(33.3)                | 6<br>(66.7)  |                       | 3<br>(22.2)                     | 7<br>(77.8)  |                       | 0<br>(0)             | 9<br>(100.0) |                       |
| PD-L1* ( <i>n</i> = 49)              |                            |              |                       |                                 |              |                       |                      |              |                       |
| ≤1%                                  | 9<br>(45.0)                | 11<br>(55.0) | 0.883                 | 14<br>(66.7)                    | 7<br>(33.3)  | 0.058                 |                      |              |                       |
| >1%                                  | 12<br>(42.9)               | 16<br>(57.1) |                       | 11<br>(39.3)                    | 17<br>(60.7) |                       |                      |              |                       |
| CD8 <sup>‡</sup> ( <i>n</i> = 49)    |                            |              |                       |                                 |              |                       |                      |              |                       |
| <median                              | 11<br>(45.8)               | 13<br>(54.2) | 0.771                 |                                 |              |                       | 14<br>(56.0)         | 11<br>(44.0) | 0.058                 |
| ≥median                              | 10<br>(41.7)               | 14<br>(58.3) |                       |                                 |              |                       | 7<br>(29.2)          | 17<br>(70.8) |                       |
| MCPyV STATUS ( <i>n</i> = 48)        |                            |              |                       |                                 |              |                       |                      |              |                       |
| Negative <sup>#</sup>                |                            |              |                       | 7<br>(70.0)                     | 3<br>(30.0)  | 0.155                 | 4<br>(40.0)          | 6<br>(60.0)  | 0.503                 |
| Positive                             |                            |              |                       | 17<br>(44.7)                    | 21<br>(55.3) |                       | 16<br>(42.1)         | 22<br>(57.9) |                       |
| GENDER ( <i>n</i> = 49)              |                            |              |                       |                                 |              |                       |                      |              |                       |
| Male                                 | 14<br>(58.3)               | 10<br>(41.7) | 0.042                 | 12<br>(50.0)                    | 12<br>(50.0) | 0.889                 | 9<br>(37.5)          | 15<br>(62.5) | 0.458                 |
| Female                               | 7<br>(29.2)                | 17<br>(70.8) |                       | 13<br>(52.0)                    | 12<br>(48.0) |                       | 12<br>(48.0)         | 13<br>(52.0) |                       |

MCPyV, Merkel Cell Polyomavirus; PD-L1, Programmed cell death ligand 1. \*% PD-L1+ tumor cells. <sup>†</sup>CD8+ tumor infiltration, overall score. <sup>#</sup>defined as negative or not assessable <sup>†</sup>p-values according to Pearson's Chi-squared test and calculated after exclusion of missing values. Significant results have been marked with bold.

**TABLE 3 |** PD-L1 and N-stage and their association with stromal CD8 infiltration.


| Clinico-pathological characteristics | Stromal CD8+ infiltration, <i>n</i> (%) |           | <i>p</i> <sup>†</sup> |
|--------------------------------------|---|-----------|-----------------------|
|                                      | <Median                                 | ≥Median   |                       |
| PD-L1* ( <i>n</i> = 49)              |   |           |                       |
| ≤1%                                  | 12 (57.1)                               | 9 (42.9)  | 0.010                 |
| > 1%                                 | 6 (21.4)                                | 22 (78.6) |                       |
| N-STAGE ( <i>n</i> = 33)             |   |           |                       |
| Negative                             | 3 (20.0)                                | 12 (80.0) | 0.037                 |
| Positive                             | 10 (55.6)                               | 8 (44.4)  |                       |

PD-L1, Programmed cell death ligand 1. \*% PD-L1+ tumor cells. <sup>†</sup>p-values according to Pearson's Chi-squared test and calculated after exclusion of missing values. Significant results have been marked with bold.


Other studies investigating anti-PD-1 antibodies Nivolumab (+/- prior chemotherapy, recruiting) and Pembrolizumab (no prior chemotherapy) reported ORR of 68 and 56%, respectively (36, 37). In our cohort, PD-L1 status, however, was not associated

with altered outcome, suggesting that this marker may be predictive for response to targeted therapy but not prognostic.

Regarding infiltration with CD8-positive cytotoxic lymphocytes, we identified a significant correlation between intratumoral CD8+ infiltration and OS, and a significant inverse correlation with nodal-stage (a widely accepted negative prognosticator for MCC). Notably, N+ disease in our cohort occurred in 54.5% of the cases while literature reports on 37% (7), a fact attributed to selection bias, as many of the patients included here were referred to the department of radiotherapy. In a larger study by Paulson et al., both clinical stage and CD8-infiltration were of prognostic relevance (10). More recent analyses of larger numbers of samples seem to confirm these assumptions (9, 38, 39) and the same was true when the specificity of T cells for MCPyV was taken to account (40). Interestingly, we did not observe any significant correlation between total tumor CD8-infiltration, PD-L1 expression, and viral load, indicating that mechanisms other than viral infection (e.g., ultraviolet radiation-induced mutations) may contribute to immune response. On the contrary, stromal infiltration with CD8+ TILs significantly correlated with both PD-L1 and



**FIGURE 2 |** Overall survival stratified by CD8 immune infiltration. **(A)** Overall survival, **(B)** Overall survival stratified by CD8 median score, **(C)** Overall survival stratified by CD8 intratumoral median score, **(D)** Overall survival stratified by CD8 stromal median score; *p*-values according to log-rank test (Mantel Cox).



**FIGURE 3 |** Patients outcome and correlation with MCPyV DNA load and PD-L1. **(A)** Overall survival stratified by MCPyV DNA median load (*n* = 48), **(B)** Overall survival stratified by PD-L1 status; MCPyV, Merkel Cell Polyomavirus; *p*-values according to log-rank test (Mantel Cox).

MCPyV. This argues for a locally restricted, viral antigene-driven immune response that failed to control the tumor in a PD-L1 dependent manner, that could be potentially reversed by ICI (41).

With respect to the correlation of MCPyV status/viral DNA load with clinical and epidemiological parameters, the most important finding in the present cohort was a significant correlation with female gender although the limited number of patients in our study does not allow definite conclusions yet. In line with that, the higher prevalence of MCPyV in female patients has been reported before, but a possible association with tumor site remains controversial (18, 42, 43). There is no molecular explanation readily available for the increased prevalence in women. A putative reason, however, may be the observation that tumors in females were diagnosed more frequently in older patients (median age females 77.0 years vs.

median age males 70.5). In line with that, Álvarez-Argüelles et al. recently speculated that there may an immunosuppressive component due to age contributing to the sex effect in MCPyV detection demonstrated in their analyses and in our study (44). Unfortunately we could not prove an association of age and viral load in our data. Another possible explanation could be a higher UV-exposure as casual factor in the male population. Yet there exist no data to undermine this speculation, although a viral etiology has been associated with female sex by many authors (18, 42, 43). Interestingly, male sex, and advanced age were associated with worse prognosis in the literature (7).

We acknowledge that the retrospective evaluation and the small number of patients is a limitation of our study. A potential calculation bias cannot be excluded. However, this is the first



study quantitatively assessing and correlating the MCPyV viral load to clinical parameters that warrant validation in larger, independent cohorts with long-term follow-up.

## CONCLUSION

These data provide important insight on the crucial role of MCPyV DNA load and TILs, in the context of PD-L1, in patients with MCC. We consider our findings on a correlation of PDL-1 with tumor localization and CD8+ Tils and a prognostic relevance of intratumoral CD8+ T cell infiltration to be in favor of a future checkpoint immunotherapy in MCC. Moreover, there is growing pre-clinical and clinical evidence on an additional improvement of the effects of checkpoint-inhibition by synergistic effects of radiation therapy (45, 46). Consequently, future clinical studies should aim to explore the effect of PD-1/PD-L1 immune-checkpoint inhibitors in combination with existing radiotherapy approaches.

## ETHICS STATEMENT

This study was carried out in accordance with the recommendations of the local ethics committee (Frankfurt University No. 4/09 UCT-03-2017) with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Frankfurt university ethics committee.

## AUTHOR CONTRIBUTIONS

JG, RW, FR, and PB conceived the idea. JG, RW, CR, and MM provided patient data and material. RW, MM, UW, and SS

contributed to the sample-preparations. RW, UW, and SS carried out the laboratory analyses. JG, RW, FR, and PB performed microscopy. JG, DM, and PB performed the statistics. JG, DM, FR, and PB analyzed and interpreted the data. FR, UW, EF, and CR were involved in the planning and supervising. JG, DM, FR, and EF drafted the manuscript and designed the figures. JG, EF, CR, FR, and PB wrote the manuscript, with contributions from the other authors. All authors read and approved the final manuscript.

## ACKNOWLEDGMENTS

The authors acknowledge Mrs. Monika Junk and Nabila Ristow for their excellent technical assistance. MCPyV-DNA testing was funded by the German National Reference Center for Papilloma- and Polyomaviruses (German Federal Ministry of Health, grant number 1369-401). All authors state that they have no potential conflict of interest relevant to this manuscript to declare. All authors have approved publication of the present manuscript.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fonc.2019.00020/full#supplementary-material>

**Supplementary Figure 1** | Patients outcome and correlation with MCPyV DNA load. Overall survival stratified by MCPyV DNA median load restricted to patients with any detectable viral DNA independent from integration status ( $n = 38$ );  $p$ -value according to log-rank test (Mantel Cox).

**Supplementary Table 1** | Association of MCPyV and gender.

**Supplementary Table 2** | Clinicopathological characteristics and their association with combined CD8/PD-L1 expression.

## REFERENCES

- van der Zwan JM, Trama A, Otter R, Larranaga N, Tavilla A, Marcos-Gragera R, et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. *Eur J Cancer* (2013) 49:2565–78. doi: 10.1016/j.ejca.2013.02.029
- Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. *Lancet Oncol*. (2016) 17:1374–85. doi: 10.1016/S1470-2045(16)30364-3
- Colunga A, Pulliam T, Nghiem P. Merkel cell carcinoma in the age of immunotherapy: facts and hopes. *Clin Cancer Res*. (2018) 24:2035–43. doi: 10.1158/1078-0432.CCR-17-0439
- FDA. Food and Drug Administration Approves First Treatment for Rare Form of Skin Cancer. (2017) Available online at: <https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm548278.htm>
- Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. *J Am Acad Dermatol*. (2010) 63:751–61. doi: 10.1016/j.jaad.2010.02.056
- Network, NCC. *NCCN Clinical Practice Guidelines in Oncology - Merkel Cell Carcinoma, Version 2.2018*. Available online at: [https://www.nccn.org/professionals/physician\\_gls/pdf/mcc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf) (Accessed June 15, 2018).
- Schadendorf D, Lebbe C, Zur Hausen A, Avril MF, Hariharan S, Bharmal M, et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. *Eur J Cancer* (2017) 71:53–69. doi: 10.1016/j.ejca.2016.10.022
- Liu W, MacDonald M, You J. Merkel cell polyomavirus infection and Merkel cell carcinoma. *Curr Opin Virol*. (2016) 20:20–27. doi: 10.1016/j.coviro.2016.07.011
- Sihto H, Bohling T, Kavola H, Koljonen V, Salmi M, Jalkanen S, et al. Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study. *Clin Cancer Res*. (2012) 18:2872–81. doi: 10.1158/1078-0432.CCR-11-3020
- Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. *J Clin Oncol*. (2011) 29:1539–46. doi: 10.1200/JCO.2010.30.6308
- Sihto H, Joensuu H. Tumor-infiltrating lymphocytes and outcome in Merkel cell carcinoma, a virus-associated cancer. *Oncoimmunology* (2012) 1:1420–1. doi: 10.4161/onci.21120
- Griffiths DA, Abdul-Sada H, Knight LM, Jackson BR, Richards K, Prescott EL, et al. Merkel cell polyomavirus small T antigen targets the NEMO adaptor protein to disrupt inflammatory signaling. *J Virol*. (2013) 87:13853–67. doi: 10.1128/JVI.02159-13
- Balermipas P, Rodel F, Rodel C, Krause M, Linge A, Lohaus F, et al. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German cancer consortium

- radiation oncology group (DKTK-ROG). *Int J Cancer* (2016) 138:171–81. doi: 10.1002/ijc.29683
14. Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, Rutegard J, et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. *Mod Pathol*. (2011) 24:671–82. doi: 10.1038/modpathol.2010.234
  15. Ferris RL, Blumenschein G, Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. *N Engl J Med*. (2016) 375:1856–67. doi: 10.1056/NEJMoa1602252
  16. Schmitt M, Wieland U, Kreuter A, Pawlita M. C-terminal deletions of Merkel cell polyomavirus large T-antigen, a highly specific surrogate marker for virally induced malignancy. *Int J Cancer* (2012) 131:2863–8. doi: 10.1002/ijc.27607
  17. Wieland U, Silling S, Scola N, Potthoff A, Gambichler T, Brockmeyer NH, et al. Merkel cell polyomavirus infection in HIV-positive men. *Arch Dermatol*. (2011) 147:401–6. doi: 10.1001/archdermatol.2011.42
  18. Sihto H, Kukko H, Koljonen V, Sankila R, Böhling T, Joensuu H. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. *J Natl Cancer Inst*. (2009) 101:938–45. doi: 10.1093/jnci/djp139
  19. Tseng YD, Parvathaneni U. Primary radiation therapy for merkel cell carcinoma. *Int J Radiat Oncol Biol Phys*. (2018) 100:14. doi: 10.1016/j.ijrobp.2017.08.029
  20. Balermipas P, Rodel F, Krause M, Linde A, Lohaus F, Baumann M, et al. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: a multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) *Int J Cancer* (2017) 141:594–603. doi: 10.1002/ijc.30770
  21. Balermipas P, Rodel F, Weiss C, Rodel C, Fokas E. Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. *Oncoimmunology* (2014) 3:e27403. doi: 10.4161/onci.27403
  22. Tseng YD, Nguyen MH, Baker K, Cook M, Redman M, Lachance K, et al. Effect of patient immune status on the efficacy of radiation therapy and recurrence-free survival among 805 patients with merkel cell carcinoma. *Int J Radiat Oncol Biol Phys*. (2018) 102:330–9. doi: 10.1016/j.ijrobp.2018.05.075
  23. Sihto H, Kukko H, Koljonen V, Sankila R, Böhling T, Joensuu H. Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in Merkel cell carcinoma. *Clin Cancer Res*. (2011) 17:4806–13. doi: 10.1158/1078-0432.CCR-10-3363
  24. Vandeven N, Lewis CW, Makarov V, Riaz N, Paulson KG, Hippe D, et al. Merkel cell carcinoma patients presenting without a primary lesion have elevated markers of immunity, higher tumor mutation burden, and improved survival. *Clin Cancer Res*. (2018) 24:963–71. doi: 10.1158/1078-0432.CCR-17-1678
  25. Touze A, Le Bidre E, Laude H, Fleury MJ, Cazal R, Arnold F, et al. High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome. *J Clin Oncol*. (2011) 29:1612–9. doi: 10.1200/JCO.2010.31.1704
  26. Bhatia K, Goedert JJ, Modali R, Preiss L, Ayers LW. Merkel cell carcinoma subgroups by Merkel cell polyomavirus DNA relative abundance and oncogene expression. *Int J Cancer* (2010) 126:2240–6. doi: 10.1002/ijc.24676
  27. Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R, et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. *Oncotarget* (2016) 7:3403–15. doi: 10.18632/oncotarget.6494
  28. Wong SQ, Waldeck K, Vergara IA, Schroder J, Madore J, Wilmott JS, et al. UV-associated mutations underlie the etiology of MCV-negative merkel cell carcinomas. *Cancer Res*. (2015) 75:5228–34. doi: 10.1158/0008-5472.CAN-15-1877
  29. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science* (2015) 348:69–74. doi: 10.1126/science.aaa4971
  30. Harms KL, Healy MA, Nghiem P, Sober AJ, Johnson TM, Bichakjian CK, et al. Analysis of prognostic factors from 9387 merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. *Ann Surg Oncol*. (2016) 23:3564–71. doi: 10.1245/s10434-016-5266-4
  31. Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, et al. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: a prospective validation study. *Cancer* (2017) 123:1464–74. doi: 10.1002/cncr.30475
  32. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *Semin Cancer Biol*. (2015) 35(Suppl.):S185–98. doi: 10.1016/j.semcancer.2015.03.004
  33. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. *Nat Rev Cancer* (2002) 2:59–65. doi: 10.1038/nrc700
  34. Peng H, Chen L, Zhang Y, Guo R, Li WF, Mao YP, et al. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. *Oncotarget* (2016) 7:24208–16. doi: 10.18632/oncotarget.8144
  35. Lin YH, Huang TL, Chien CY, Chen HC, Hsu HC, Huang EY, et al. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy. *Radiat Oncol*. (2018) 13:45. doi: 10.1186/s13014-018-0990-5
  36. Nghiem PT, Bhatia S, Lipsen EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. *N Engl J Med*. (2016) 374:2542–52. doi: 10.1056/NEJMoa1603702
  37. Topalian SL, Bhatia S, Hollebecque A, Awada A, De Boer JP, Kudchadkar RR, et al. Abstract CT074: non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC). *Cancer Res*. (2017) 77(13 Suppl.):CT074. doi: 10.1158/1538-7445.am2017-ct074
  38. Kervarec T, Gaboriaud P, Berthon P, Zaragoza J, Schrama D, Houben R, et al. Merkel cell carcinomas infiltrated with CD33(+) myeloid cells and CD8(+) T cells are associated with improved outcome. *J Am Acad Dermatol*. (2018) 78:973–82 e8. doi: 10.1016/j.jaad.2017.12.029
  39. Paulson KG, Iyer JG, Simonson WT, Blom A, Thibodeau RM, Schmidt M, et al. CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study. *Am J Clin Pathol*. (2014) 142:452–8. doi: 10.1309/AJCPKIDZM39CRPNC
  40. Miller NJ, Church CD, Dong L, Crispin D, Fitzgibbon MP, Lachance K, et al. Tumor-infiltrating merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival. *Cancer Immunol Res*. (2017) 5:137–47. doi: 10.1158/2326-6066.CIR-16-0210
  41. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. *Nat Rev Cancer* (2016) 16:275–87. doi: 10.1038/nrc.2016.36
  42. Coursaget P, Samimi M, Nicol JT, Gardair C, Touze A. Human merkel cell polyomavirus: virological background and clinical implications. *APMIS* (2013) 121:755–69. doi: 10.1111/apm.12122
  43. Paik JY, Hall G, Clarkson A, Lee L, Toon C, Colebatch A, et al. Immunohistochemistry for Merkel cell polyomavirus is highly specific but not sensitive for the diagnosis of Merkel cell carcinoma in the Australian population. *Hum Pathol*. (2011) 42:1385–90. doi: 10.1016/j.humpath.2010.12.013
  44. Alvarez-Arguelles ME, Melon S, Rojo S, Fernandez-Blazquez A, Boga JA, Palacio A, et al. Detection and quantification of Merkel cell polyomavirus. Analysis of Merkel cell carcinoma cases from 1977 to 2015. *J Med Virol*. (2017) 89:2224–9. doi: 10.1002/jmv.24896
  45. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. *Lancet Oncol*. (2015) 16:e498–509. doi: 10.1016/S1470-2045(15)00007-8
  46. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. *JAMA Oncol*. (2015) 1:1325–32. doi: 10.1001/jamaoncol.2015.2756

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 von der Grün, Winkelmann, Meissner, Wieland, Silling, Martin, Fokas, Rödel, Rödel and Balermipas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.